上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (3): 290-.doi: 10.3969/j.issn.1674-8115.2011.03.009

• 论著（临床研究） • 上一篇    下一篇

晚期非小细胞肺癌组织中ERCC1、RRM1和BRCA1的表达研究

高志强, 韩宝惠, 沈 洁, 顾爱琴, 戚大江, 黄进肃, 施春雷, 熊丽纹, 赵怡卓, 姜丽岩, 王慧敏, 陈玉蓉   

  1. 上海交通大学附属胸科医院肺内科, 上海 200030
  • 出版日期:2011-03-28 发布日期:2011-03-29
  • 通讯作者: 韩宝惠, 电子信箱: xkyyhan@gmail.com。
  • 作者简介:高志强（1975—）, 男, 主治医师, 博士；电子信箱: zhiqiangg@163.com。
  • 基金资助:

    上海市科委科技发展基金（06DZ19501）和上海市科委学科带头人计划项目（09XD1403500）

Expression of ERCC1, RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer

GAO Zhi-qiang, HAN Bao-hui, SHEN Jie, GU Ai-qin, QI Da-jiang, HUANG Jin-su, SHi Chun-lei, XIONG Li-wen, ZHAO Yi-zhuo, JIANG Li-yan, WANG Hui-min, CHEN Yu-rong   

  1. Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
  • Online:2011-03-28 Published:2011-03-29
  • Supported by:

    Shanghai Science and Technology Committee Foundation, 06DZ19501, 09XD1403500

PDF (PC)

1616

摘要：

目的 探讨晚期非小细胞肺癌（NSCLC）组织中DNA修复基因家族成员ERCC1、RRM1和BRCA1的表达及其临床意义。方法 应用免疫组织化学方法对122例晚期NSCLC组织进行ERCC1、RRM1及BRCA1蛋白表达检测。回顾性分析NSCLC患者的临床特征、化疗反应及预后与肿瘤组织中ERCC1、RRM1和BRCA1蛋白表达的关系。结果 122例晚期NSCLC组织中ERCC1、RRM1和BRCA1蛋白表达阳性率分别为47.5%、35.2%和46.7%。ERCC1和RRM1蛋白表达阳性率与患者的性别、年龄、吸烟状况、体力状况ECOG评分及肿瘤临床分期和组织学类型均无明显相关性(P>0.05)；女性患者肿瘤组织BRCA1蛋白表达阳性率(63.6%)显著高于男性患者(40.4%)。ERCC1和BRCA1蛋白表达阳性与阴性患者的化疗有效率、中位生存期和1年生存率比较差异均无统计学意义(P>0.05)；RRM1蛋白表达阳性患者的化疗有效率和1年生存率均显著低于RRM1蛋白表达阴性患者（P<0.05）。结论 肿瘤组织中RRM1蛋白表达与晚期NSCLC患者的化疗疗效及预后密切相关。

关键词: DNA修复基因家族, ERCC1, RRM1, BRCA1, 预后, 非小细胞肺癌

Abstract:

Objective To investigate the expression of DNA repair gene family members of ERCC1, RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer (NSCLC), and explore its clinical significance. Methods The expression of ERCC1, RRM1 and BRCA1 protein in 122 cases of advanced NSCLC was detected by immunohistochemical methods. The relationship between the expression of ERCC1, RRM1 and BRCA1 protein and the clinical characteristics, response to chemotherapy and prognosis were explored. Results The positive expression of ERCC1, RRM1 and BRCA1 protein in 122 cases was 47.5%, 35.2% and 46.7%, respectively. There was no significant correlation between the positive expression of ERCC1 and RRM1 protein and gender, age, smoking status, ECOG physical status scale score, clinical stages and histological types  (P>0.05), and the expression of BRCA1 protein in females (63.6%) was significantly higher than that in males (40.4%). There was no significant difference in response rates to chemotherapy, median survival time and 1-year survival rate between patients with positive expression of ERCC1 and BRCA1 protein and those with negative expression of ERCC1 and BRCA1 protein (P>0.05). Patients with positive expression of RRM1 protein had significantly lower response rates to chemotherapy and 1-year survival rate than those with negative expression of RRM1 protein (P<0.05). Conclusion The expression of RRM1 protein in cancer tissues is closely related to the response to chemotherapy and prognosis in patients with advanced NSCLC.

Key words: DNA repair gene family, ERCC1, RRM1, BRCA1, prognosis, non-small cell lung cancer